Vuong Nguyen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1950485/publications.pdf

Version: 2024-02-01

86	1,789	411340	355658
papers	citations	20 h-index	38 g-index

86	86	86	1911
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema. British Journal of Ophthalmology, 2023, 107, 79-83.	2.1	6
2	Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry. British Journal of Ophthalmology, 2023, 107, 842-848.	2.1	3
3	Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration. Eye, 2023, 37, 467-473.	1.1	4
4	Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion. Eye, 2023, 37, 1145-1154.	1.1	3
5	Initial observation or treatment for diabetic macular oedema with good visual acuity: twoâ€year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry. Acta Ophthalmologica, 2022, 100, 285-294.	0.6	3
6	Predictors of progression in untreated keratoconus: a Save Sight Keratoconus Registry study. British Journal of Ophthalmology, 2022, 106, 1206-1211.	2.1	19
7	THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2022, 42, 95-106.	1.0	6
8	12â€month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry. Acta Ophthalmologica, 2022, 100, .	0.6	7
9	Comparative study of 2â€year outcomes for <scp>Hydrus</scp> or <scp>iStent</scp> inject microinvasive glaucoma surgery implants with cataract surgery. Clinical and Experimental Ophthalmology, 2022, 50, 303-311.	1.3	19
10	Quality of life impact of eye diseases: a Save Sight Registries study. Clinical and Experimental Ophthalmology, 2022, 50, 386-397.	1.3	15
11	Creation of a neovascular ageâ€related macular degeneration national database using a webâ€based platform: <scp>Fight Retinal Blindness Spain.</scp> Report 1: Visual outcomes. Clinical and Experimental Ophthalmology, 2022, 50, 312-324.	1.3	5
12	Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry. Ophthalmology and Therapy, 2022, 11, 797-810.	1.0	4
13	Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular ageâ€related macular degeneration in daily clinical practice: data from the FRB! registry. Acta Ophthalmologica, 2022, 100, .	0.6	8
14	Characterization of Poor Visual Outcomes of Diabetic Macular Edema: The Fight Retinal Blindness! Project. Ophthalmology Retina, 2022, 6, 540-547.	1.2	3
15	INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL THERAPY OUTCOMES. Retina, 2022, 42, 616-627.	1.0	11
16	Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases. Ophthalmology Retina, 2022, 6, 1044-1053.	1.2	2
17	Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular ageâ€"related macular degeneration: real world data from the Fight Retinal Blindness registry. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1463-1470.	1.0	10
18	Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry. British Journal of Ophthalmology, 2021, , bjophthalmol-2020-318491.	2.1	5

#	Article	IF	Citations
19	Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry. Eye, 2021, , .	1.1	4
20	Effect of intravitreal injection speed on acute rise in intraocular pressure. The SPEED IOP study. Clinical and Experimental Ophthalmology, 2021, 49, 519-521.	1.3	1
21	Comparative Efficacy and Safety of Standard Versus Accelerated Corneal Crosslinking for Keratoconus: 1-Year Outcomes From the Save Sight Keratoconus Registry Study. Cornea, 2021, 40, 1581-1589.	0.9	14
22	Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2â€year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry. Acta Ophthalmologica, 2021, , .	0.6	4
23	Neovascular ageâ€related macular degeneration: A review of findings from the realâ€world Fight Retinal Blindness! registry. Clinical and Experimental Ophthalmology, 2021, 49, 652-663.	1.3	15
24	Neovascular ageâ€related macular degeneration at treatment intervals of 14â€‰weeks or greater. Clinical and Experimental Ophthalmology, 2021, 49, 570-578.	1.3	2
25	Outer Retinal Layer Thickening Predicts the Onset of Exudative Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2021, 231, 19-27.	1.7	10
26	FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2021, 41, 118-124.	1.0	7
27	ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR. Retina, 2021, 41, 1446-1454.	1.0	4
28	Realâ€world treatment outcomes of neovascular Ageâ€related Macular Degeneration in the Netherlands. Acta Ophthalmologica, 2021, 99, e884-e892.	0.6	8
29	Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis. Translational Vision Science and Technology, 2021, 10, 5.	1.1	4
30	Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry. BMJ Open Ophthalmology, 2021, 6, e000903.	0.8	3
31	Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. American Journal of Ophthalmology, 2020, 210, 116-124.	1.7	53
32	Outcomes of cataract surgery in eyes with diabetic macular oedema: Data from the Fight Retinal Blindness! Registry. Clinical and Experimental Ophthalmology, 2020, 48, 462-469.	1.3	9
33	Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 369-376.	2.5	16
34	SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 1696-1703.	1.0	5
35	Ranibizumab or Aflibercept for Diabetic Macular Edema. Ophthalmology, 2020, 127, 608-615.	2.5	42
36	ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 866-872.	1.0	6

#	Article	IF	Citations
37	The Impact on Work Patterns of Implementing the Save Sight Keratoconus Registry in the Hospital Setting. Cornea, 2020, 39, 451-456.	0.9	5
38	Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project. British Journal of Ophthalmology, 2020, 104, 1064-1069.	2.1	10
39	Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice. Ophthalmology Retina, 2020, 4, 861-870.	1.2	14
40	Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye, 2020, 35, 2793-2801.	1.1	16
41	PREVALENCE AND RISK FACTORS FOR THE DEVELOPMENT OF PHYSICIAN-GRADED SUBRETINAL FIBROSIS IN EYES TREATED FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 2285-2295.	1.0	27
42	Microbial keratitis in Sydney, Australia: risk factors, patient outcomes, and seasonal variation. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1745-1755.	1.0	64
43	Changes in realâ€world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5â€year outcomes: Data from the Fight Retinal Blindness! Registry. Clinical and Experimental Ophthalmology, 2020, 48, 802-812.	1.3	10
44	Fourâ€week outcomes of vascular endothelial growth factor inhibitors for neovascular ageâ€related macular degeneration. Clinical and Experimental Ophthalmology, 2020, 48, 946-955.	1.3	1
45	Bruch's Membrane Opening Minimum Rim Width Provides Objective Differentiation between Glaucoma and Nonglaucomatous Optic Neuropathies. American Journal of Ophthalmology, 2020, 218, 164-172.	1.7	13
46	Reply. Ophthalmology, 2020, 127, e21-e22.	2.5	1
47	Tenâ€year outcomes of antiâ€vascular endothelial growth factor treatment for neovascular ageâ€related macular disease: A singleâ€centre French study. Clinical and Experimental Ophthalmology, 2020, 48, 636-643.	1.3	23
48	Biomarkers in Usher syndrome: ultra-widefield fundus autofluorescence and optical coherence tomography findings and their correlation with visual acuity and electrophysiology findings. Documenta Ophthalmologica, 2020, 141, 205-215.	1.0	3
49	A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion. Eye, 2020, 34, 1770-1796.	1.1	28
50	Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: a comparison between two treatment regimens. British Journal of Ophthalmology, 2020, 104, 1052-1056.	2.1	20
51	No association between sleep apnoea and macular telangiectasia type 2 and its markers of severity and progression: a caseâ€“control study and retrospective cohort study. Clinical and Experimental Ophthalmology, 2019, 47, 63-68.	1.3	2
52	Dexamethasone implant for the treatment of persistent diabetic macular oedema despite longâ€term treatment with bevacizumab. Clinical and Experimental Ophthalmology, 2019, 47, 287-289.	1.3	5
53	Consequences of neglecting cryptic life stages from demographic models. Ecological Modelling, 2019, 408, 108723.	1.2	18
54	Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. Ophthalmology Retina, 2019, 3, 623-628.	1.2	31

#	Article	IF	Citations
55	Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. American Journal of Ophthalmology, 2019, 204, 105-112.	1.7	19
56	Development of New Proliferative Diabetic Retinopathy in the BEVORDEX Trial. Ophthalmology Retina, 2019, 3, 286-287.	1.2	6
57	Keratoconus Natural Progression. Ophthalmology, 2019, 126, 935-945.	2.5	157
58	Vision-Related Quality of Life in Keratoconus: A Save Sight Keratoconus Registry Study. Cornea, 2019, 38, 600-604.	0.9	35
59	A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy. Ophthalmology Retina, 2019, 3, 220-229.	1.2	16
60	Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Antiâ€“Vascular Endothelial Growth Factor Agents. Ophthalmology, 2019, 126, 735-742.	2.5	31
61	Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study. British Journal of Ophthalmology, 2019, 103, 1158-1162.	2.1	1
62	Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months. British Journal of Ophthalmology, 2019, 103, 1337-1341.	2.1	14
63	Tumour Expression of Histone Deacetylases in Uveal Melanoma. Ocular Oncology and Pathology, 2019, 5, 153-161.	0.5	11
64	Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 64-74.	2.5	22
65	Relationship between reticular pseudodrusen and choroidal thickness in intermediate ageâ€related macular degeneration: comment. Clinical and Experimental Ophthalmology, 2018, 46, 966-967.	1.3	1
66	Outcomes in Neovascular Age-Related Macular Degeneration when Neovascular Lesion Activity Is Uncertain: Observational Study. Ophthalmology Retina, 2018, 2, 531-538.	1.2	2
67	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Progress in Retinal and Eye Research, 2018, 65, 127-146.	7.3	205
68	Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. The Cochrane Library, 2018, 2018, CD011599.	1.5	37
69	Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project. American Journal of Ophthalmology, 2018, 190, 50-57.	1.7	18
70	TWO YEAR OUTCOMES OF â€œTREAT AND EXTENDâ€•INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2018, 38, 20-28.	1.0	83
71	Early and Late Retinal Pigment Epithelium Tears after Antiâ€“Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2018, 125, 237-244.	2.5	16
72	Realâ€world visual outcomes in patients with neovascular ageâ€related macular degeneration receiving aflibercept at fixed intervals as per UK licence. Clinical and Experimental Ophthalmology, 2018, 46, 407-411.	1.3	24

#	Article	IF	Citations
73	The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial. Ophthalmology Retina, 2018, 2, 231-234.	1.2	13
74	Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular ageâ€related macular degeneration: a prospective study from a longâ€term observational data set. The Fight Retinal Blindness! Project. Clinical and Experimental Ophthalmology, 2018, 46, 266-274.	1.3	4
75	Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema. British Journal of Ophthalmology, 2018, 102, 479-482.	2.1	12
76	RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2018, 38, 1954-1961.	1.0	6
77	Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. Ophthalmology, 2018, 125, 66-74.	2.5	73
78	A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013â€“2016. The Fight Retinal Blindness! Project. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1839-1846.	1.0	13
79	Making the most of incomplete long-term datasets: the MARSS solution. Australian Zoologist, 2018, 39, 733-747.	0.6	3
80	Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, etÂal.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761). Ophthalmology, 2017, 124, e31-e32.	2.5	19
81	Population dynamics of desert mammals: similarities and contrasts within a multispecies assemblage. Ecosphere, 2016, 7, e01343.	1.0	41
82	METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 1418-1431.	1.0	145
83	Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology, 2016, 123, 2545-2553.	2.5	59
84	Spatial and temporal synchrony in reptile population dynamics in variable environments. Oecologia, 2016, 182, 475-485.	0.9	15
85	Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 2393-2400.	2.5	47
86	On the validity of visual cover estimates for time series analyses: a case study of hummock grasslands. Plant Ecology, 2015, 216, 975-988.	0.7	10